newsfilter
← Latest News
Lightspeed Venture Partners·

Why We’re Backing Warp

Summary

  • Warp launched today with a Series A round led by Lightspeed to build AI-driven robotic labs for drug discovery chemistry.
  • The company aims to accelerate drug discovery & bring this work back to the US amid rising costs & low approval rates.
  • Drug development is slow because manual lab work rarely exceeds ten reactions per day & lacks compounding process expertise.
  • Western pharma currently outsources most chemistry offshore to China, but the 2025 BIOSECURE Act & recent Department of War designations are pushing for domestic alternatives.
  • US companies face an estimated eight-year gap to replace offshore partners without disrupting programs.
  • AI models are limited by a lack of public data on failed experiments, which are critical for training accurate prediction models.
  • Warp records all experimental steps including failures to optimize lab processes & train models to select the best compounds.
  • Early operations involve expert chemists using AI tools, with robots gradually taking over repetitive tasks to scale operations 24/7.
  • The founding team includes CEO Kevin Weil (ex-OpenAI), COO DJ Patil (ex-US Chief Data Scientist), CSO Sol Reisberg (20 years in medicinal chemistry), & co-founder Mano Paluri (ex-Meta AI).
  • Advances in lab robotics & AI models now enable continuous learning loops that were previously impossible.
  • Lightspeed invested due to Warp's unique position to capture the opportunity at the intersection of AI, robotics, & life sciences.

Warp builds AI-driven robotic labs that run drug discovery chemistry for pharma and biotech companies. Its goal is to both speed up drug discovery and bring this work back to the US.

Keywords
AI